• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

可能将 CXCL12 和 CXCR4 作为肿瘤标志物应用于乳腺癌患者的诊断。

Possible Diagnostic Application of CXCL12 and CXCR4 as Tumor Markers in Breast Cancer Patients.

机构信息

Department of Esthetic Medicine, Medical University of Bialystok, Bialystok, Poland

Department of Esthetic Medicine, Medical University of Bialystok, Bialystok, Poland.

出版信息

Anticancer Res. 2020 Jun;40(6):3221-3229. doi: 10.21873/anticanres.14303.

DOI:10.21873/anticanres.14303
PMID:32487616
Abstract

BACKGROUND/AIM: Chemokines are cytokines involved not only in inflammatory but also in inappropriate response of the immune system in breast cancer (BC) progression. We examined the diagnostic usefulness of CXCL12, CXCR4 and CA 15-3 in BC patients, based on ROC curve analysis.

MATERIALS AND METHODS

The study group consisted of 100 patients with BC; the control group consisted of 35 women with benign breast disease and 35 healthy patients. The median concentration of chemokines was measured by ELISA and that of CA 15-3 by chemiluminescent microparticle immunoassay.

RESULTS

The concentrations of CXCL12 and CXCR4 in the BC group were significantly higher than those in the control groups. The AUC value of CXCL12 (0.7502) was the highest of all the chemokines measured in the BC patients.

CONCLUSION

There may be a link between CXCL12, CXCR4 and BC that can assist in the diagnosis, markedly when combined with CA 15-3.

摘要

背景/目的:趋化因子不仅参与炎症反应,还参与乳腺癌(BC)进展中免疫系统的异常反应。我们通过 ROC 曲线分析,检查了 CXCL12、CXCR4 和 CA 15-3 在 BC 患者中的诊断价值。

材料和方法

研究组包括 100 例 BC 患者,对照组包括 35 例良性乳腺疾病患者和 35 例健康患者。通过 ELISA 测量趋化因子的中位数浓度,通过化学发光微粒子免疫测定法测量 CA 15-3 的浓度。

结果

BC 组的 CXCL12 和 CXCR4 浓度明显高于对照组。在 BC 患者中测量的所有趋化因子中,CXCL12 的 AUC 值(0.7502)最高。

结论

CXCL12、CXCR4 与 BC 之间可能存在联系,有助于诊断,尤其是与 CA 15-3 联合使用时。

相似文献

1
Possible Diagnostic Application of CXCL12 and CXCR4 as Tumor Markers in Breast Cancer Patients.可能将 CXCL12 和 CXCR4 作为肿瘤标志物应用于乳腺癌患者的诊断。
Anticancer Res. 2020 Jun;40(6):3221-3229. doi: 10.21873/anticanres.14303.
2
Androgen Triggers the Pro-Migratory CXCL12/CXCR4 Axis in AR-Positive Breast Cancer Cell Lines: Underlying Mechanism and Possible Implications for the Use of Aromatase Inhibitors in Breast Cancer.雄激素激活AR阳性乳腺癌细胞系中促迁移的CXCL12/CXCR4轴:潜在机制及芳香化酶抑制剂在乳腺癌治疗中应用的潜在意义
Cell Physiol Biochem. 2017;44(1):66-84. doi: 10.1159/000484584. Epub 2017 Nov 3.
3
Prognostic significance of CXCL12, CXCR4, and CXCR7 in patients with breast cancer.CXCL12、CXCR4和CXCR7在乳腺癌患者中的预后意义。
Int J Clin Exp Pathol. 2015 Oct 1;8(10):13217-24. eCollection 2015.
4
Upregulation of CXC chemokine receptor 4-CXC chemokine ligand 12 axis ininvasive breast carcinoma: A potent biomarker predicting lymph node metastasis.侵袭性乳腺癌中CXC趋化因子受体4-CXC趋化因子配体12轴的上调:一种预测淋巴结转移的有效生物标志物。
J Cancer Res Ther. 2018 Jan-Mar;14(2):345-350. doi: 10.4103/0973-1482.177221.
5
CXCR4/CXCL12 Signaling and Protumor Macrophages in Primary Tumors and Sentinel Lymph Nodes Are Involved in Luminal B Breast Cancer Progression.CXCR4/CXCL12 信号和原肿瘤及前哨淋巴结中的促肿瘤巨噬细胞参与腔 B 型乳腺癌的进展。
Dis Markers. 2018 Apr 16;2018:5018671. doi: 10.1155/2018/5018671. eCollection 2018.
6
The CXCL12-CXCR4 chemokine pathway: a novel axis regulates lymphangiogenesis.CXCL12-CXCR4 趋化因子通路:调控淋巴管生成的新轴。
Clin Cancer Res. 2012 Oct 1;18(19):5387-98. doi: 10.1158/1078-0432.CCR-12-0708. Epub 2012 Aug 29.
7
Hormone receptor-independent CXCL10 production is associated with the regulation of cellular factors linked to breast cancer progression and metastasis.不依赖激素受体的CXCL10生成与调控和乳腺癌进展及转移相关的细胞因子有关。
Exp Mol Pathol. 2015 Aug;99(1):163-72. doi: 10.1016/j.yexmp.2015.06.002. Epub 2015 Jun 14.
8
Epigenetic changes of CXCR4 and its ligand CXCL12 as prognostic factors for sporadic breast cancer.CXCR4 及其配体 CXCL12 的表观遗传改变作为散发性乳腺癌的预后因素。
PLoS One. 2011;6(12):e29461. doi: 10.1371/journal.pone.0029461. Epub 2011 Dec 29.
9
CXCL12/CXCR4 signal transduction in diseases and its molecular approaches in targeted-therapy.CXCL12/CXCR4 信号转导在疾病中的作用及其在靶向治疗中的分子方法。
Immunol Lett. 2020 Jan;217:91-115. doi: 10.1016/j.imlet.2019.11.007. Epub 2019 Nov 17.
10
Tissue Expression and Prognostic Role of CXCL12 and CXCR4 in High-grade Serous Ovarian Carcinoma.CXCL12 和 CXCR4 在高级别浆液性卵巢癌中的组织表达和预后作用。
Anticancer Res. 2023 Jul;43(7):3331-3340. doi: 10.21873/anticanres.16509.

引用本文的文献

1
The novel functions of chemokines in lung cancer progression.趋化因子在肺癌进展中的新功能。
Front Immunol. 2025 Jun 18;16:1607225. doi: 10.3389/fimmu.2025.1607225. eCollection 2025.
2
Targeting Matrix Metalloproteinases and Their Inhibitors in Melanoma.靶向黑色素瘤中的基质金属蛋白酶及其抑制剂
Int J Mol Sci. 2024 Dec 18;25(24):13558. doi: 10.3390/ijms252413558.
3
Heterodimers Are an Integral Component of Chemokine Signaling Repertoire.异源二聚体是趋化因子信号谱的一个组成部分。
Int J Mol Sci. 2023 Jul 19;24(14):11639. doi: 10.3390/ijms241411639.
4
CXCL12 and CXCR4 as Potential Early Biomarkers for Luminal A and Luminal B Subtypes of Breast Cancer.CXCL12和CXCR4作为 Luminal A型和Luminal B型乳腺癌潜在的早期生物标志物
Cancer Manag Res. 2023 Jul 4;15:573-589. doi: 10.2147/CMAR.S416382. eCollection 2023.
5
Plasma Levels of CXC Motif Chemokine 1 (CXCL1) and Chemokine 8 (CXCL8) as Diagnostic Biomarkers in Luminal A and B Breast Cancer.CXC基序趋化因子1(CXCL1)和趋化因子8(CXCL8)的血浆水平作为腔面A型和B型乳腺癌的诊断生物标志物
J Clin Med. 2022 Nov 12;11(22):6694. doi: 10.3390/jcm11226694.
6
A new obligate CXCL4-CXCL12 heterodimer for studying chemokine heterodimer activities and mechanisms.一种新的必需的 CXCL4-CXCL12 异二聚体,用于研究趋化因子异二聚体的活性和机制。
Sci Rep. 2022 Oct 13;12(1):17204. doi: 10.1038/s41598-022-21651-0.
7
CXC Chemokine Signaling in Progression of Epithelial Ovarian Cancer: Theranostic Perspectives.CXC 趋化因子信号在卵巢上皮性癌进展中的作用:治疗诊断学展望。
Int J Mol Sci. 2022 Feb 27;23(5):2642. doi: 10.3390/ijms23052642.
8
Cooperation between Angiogenesis, Vasculogenesis, Chemotaxis, and Coagulation in Breast Cancer Metastases Development: Pathophysiological Point of View.血管生成、血管发生、趋化作用和凝血在乳腺癌转移发展中的协同作用:病理生理学视角
Biomedicines. 2022 Jan 27;10(2):300. doi: 10.3390/biomedicines10020300.